Advanced Cell Technology Inc., of Marlborough, Mass., said that the vision of a patient enrolled in a clinical investigation of the company's retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) has improved from 20/400 to 20/40 following treatment...Stem Cell Therapeutics Corp., of Toronto, said its wholly owned subsidiary Trillium Therapeutics has completed dosing in its Phase I study of TTI-1612 in patients with interstitial cystitis/bladder pain syndrome (IC
Ltd., of Germantown, Md., said it filed an investigational new drug application (IND) to begin clinical trials of its adipose-derived stem cell product, RNL-JointStem, for the treatment of osteoarthritis
TikoMed AB, of Viken, Sweden, initiated a Phase I/II study of orphan drug candidate TM-400, designed to improve the outcome of hematopoietic stem cell transplantation in hematological cancers such as multiple myeloma and non-Hodgkins lymphoma...The treatment increases the harvest of stem cells and improves the cell mixture for transplantation, with previous studies suggesting the product has a superior profile compared to existing treatment
Chimerix Inc., of Durham, N.C., said that its Phase III SUPPRESS trial of CMX001 for cytomegalovirus following allogeneic hematopoietic stem cell transplant now has a finalized design for population, endpoints, dosing and duration of therapy
Advanced Cell Technology Inc., of Marlborough, Mass., said the first subject in the third dosage cohort was injected with 150,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells in its European Phase I trial for Stargardt's macular dystrophy (SMD
StemCells Inc., of Newark, Calif., added the Byers Eye Institute at Stanford University in Palo Alto, Calif., as a second site for the Phase I/II trial of its purified human neural stem cell candidate in dry age-related macular degeneration
Athersys Inc., of Cleveland, said the UK's Medicines and Healthcare Products Regulatory Agency approved its application to expand the ongoing Phase II study of MultiStem therapy, an off-the-shelf stem cell product, to patients who have suffered an ischemic stroke...Neuralstem Inc., of Rockville, Md., said it received approval from the FDA to start a Phase II trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis
In the prospective, randomized study, patients with chronic heart failure secondary to ischemic cardiomyopathy received treatment with their own stem cells engineered to become progenitors of cardiac cells
Millennium: The Takeda Oncology Co., of Cambridge, Mass., said data from a meta-analysis of Velcade (bortezomib)-based regimens compared to non-Velcade-based regimens as induction therapy prior to autologous stem cell transplant in patients with previously untreated multiple myeloma
Advanced Cell Technology Inc., of Santa Monica, Calif., treated patients in a third cohort of each of its two Phase I trials of human embryonic stem cell-(hESC) derived retinal pigment epithelial cells for macular degeneration
Cellular Biomedicine Group, of Palo Alto, Calif., launched a clinical trial for TC-DC (Tumor Stem Cell-Specific Dendritic Cell) therapy for hepatocellular carcinoma...The trial is the result of collaboration between CBMG, California Stem Cell and Shanghai's PLA 85 Hospital
Advanced Cell Technology Inc., of Santa Monica, Calif., said an independent data and safety monitoring board authorized the firm to move forward with enrollment and treatment of patients in the next cohort of each of its three ongoing trials of human embryonic stem cell-derived retinal pigment epithelial cells for eye diseases
Kiadis Pharma BV, of Amsterdam, the Netherlands, said it received a No Objection Letter from Canadian regulators to proceed with a Phase II study testing ATIR, a cell-based product designed to enable stem cell transplantation from mismatched family donors
Chimerix Inc., of Research Triangle Park, N.C., presented data during the Allogeneic Transplants Poster Session at the BMT Tandem Meetings in Salt Lake City over the weekend, including data from a Phase II study testing CMX001 for the prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation
CDX-301 is a cytokine that stimulates the expansion and differentiation of hematopoietic progenitor and stem cells...Gamida Cell Ltd., of Jerusalem, disclosed results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's NAM technology
Steven Schwartz, professor of ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute, plans to lead a Phase I/II study using ACT's retinal pigment epithelial (RPE) cells, derived from human embryonic stem cells (hESC), to treat myopic macular degeneration, commonly known as nearsightedness
Ltd., of Seoul, South Korea, said it filed an investigational new drug application with Korean regulators to start Phase II and Phase III studies testing its RNL-Astrostem stem cell drug in patients with cerebral palsy...Data from a Phase I trial showed that the product, an intravenous infusion of human adipose tissue-derived mesenchymal stem cells, suggested potential efficacy in the disease
Advanced Cell Technology Inc., of Marlborough, Mass., said that the vision of a patient enrolled in a clinical investigation of the company's retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) has improved from 20/400 to 20/40 following treatment...Stem Cell Therapeutics Corp., of Toronto, said its wholly owned subsidiary Trillium Therapeutics has completed dosing in its Phase I study of TTI-1612 in patients with interstitial cystitis/bladder pain syndrome (IC